Urogen Pharma Statistics
Want to see URGN full AI Analyst Report?
Urogen Pharma (URGN) Stock Statistics & Valuation Metrics
Total Valuation
Urogen Pharma has a market cap or net worth of $1.28B. The enterprise value is $2.16B.
- Market Cap
- $1.28B
- Enterprise Value
- $2.16B
Share Statistics
Urogen Pharma has 49,047,825 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 49,047,825
- Owned by Insiders
- 1.77%
- Owned by Institutions
- 23.62%
Financial Efficiency
Urogen Pharma’s return on equity (ROE) is 1.46 and return on invested capital (ROIC) is -81.06%.
- Return on Equity (ROE)
- 1.46
- Return on Assets (ROA)
- -0.77
- Return on Invested Capital (ROIC)
- -81.06%
- Return on Capital Employed (ROCE)
- -0.81
- Revenue Per Employee
- 365.96K
- Profits Per Employee
- -511.65K
- Employee Count
- 300
- Asset Turnover
- 0.55
- Inventory Turnover
- 0.76
Valuation Ratios
The current PE Ratio of Urogen Pharma is -19.88. Urogen Pharma’s PEG ratio is -0.18.
- PE Ratio
- -19.88
- PS Ratio
- 5.14
- PB Ratio
- -10.59
- Price to FCF
- -9.74
- Price to Operating Cash Flow
- -10.06
- PEG Ratio
- -0.18
Income Statement
In the last 12 months, Urogen Pharma had revenue of 109.79M and earned -153.49M in profits. Earnings per share was -3.19.
- Revenue
- 109.79M
- Gross Profit
- 97.34M
- Operating Income
- -124.86M
- Pretax Income
- -153.42M
- Net Income
- -153.49M
- EBITDA
- -135.66M
- Earnings Per Share (EPS)
- -3.19
Cash Flow
In the last 12 months, operating cash flow was -131.85M and capital expenditures -203,000, giving a free cash flow of -132.05M billion.
- Operating Cash Flow
- -131.85M
- Free Cash Flow
- -132.05M
- Free Cash Flow per Share
- -2.61
Dividends & Yields
Urogen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.20%
- Earnings Yield
- -4.93%
Stock Price Statistics
- Beta
- 1.41
- 52-Week Price Change
- 4.97%
- 50-Day Moving Average
- 38.10
- 200-Day Moving Average
- 31.80
- Relative Strength Index (RSI)
- 27.80
- Average Volume (3m)
- 1.00M
Important Dates
Urogen Pharma upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Urogen Pharma as a current ratio of 4.01, with Debt / Equity ratio of -121.67%
- Current Ratio
- 4.01
- Quick Ratio
- 3.65
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- -0.13
- Interest Coverage Ratio
- -3.69
Taxes
In the past 12 months, Urogen Pharma has paid 78.00K in taxes.
- Income Tax
- 78.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Urogen Pharma EV to EBITDA ratio is -35.23, with an EV/FCF ratio of -10.64.
- EV to Sales
- 5.61
- EV to EBITDA
- -35.23
- EV to Free Cash Flow
- -10.64
- EV to Operating Cash Flow
- -10.66
Balance Sheet
Urogen Pharma has $90.55M in cash and marketable securities with $196.28M in debt, giving a net cash position of -$105.73M billion.
- Cash & Marketable Securities
- $90.55M
- Total Debt
- $196.28M
- Net Cash
- -$105.73M
- Net Cash Per Share
- -$2.16
- Tangible Book Value Per Share
- -$2.48
Margins
Gross margin is 91.41%, with operating margin of -12.36%, and net profit margin of -26.27%.
- Gross Margin
- 91.41%
- Operating Margin
- -12.36%
- Pretax Margin
- -25.64%
- Net Profit Margin
- -26.27%
- EBITDA Margin
- -15.94%
- EBIT Margin
- -16.77%
Analyst Forecast
The average price target for Urogen Pharma is $62.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $62.20
- Price Target Upside
- 135.70% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 159.29%
- EPS Growth Forecast
- 61.62%
Scores
- Smart Score
- 9
- AI Score
- 49
